Trials / Completed
CompletedNCT02959060
A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects
An Open-Label, Single-Sequence Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study is to evaluate the effect of rifampin on the single-dose pharmacokinetics (PK) of BMS-986177 in healthy participants with parameters like Cmax, AUC(INF), AUC(0-T)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986177 | Single dose of BMS-986177 and multiple doses of Rifampin |
| DRUG | Rifampin | Single dose of BMS-986177 and multiple doses of Rifampin |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2016-11-08
- Last updated
- 2017-01-06
Source: ClinicalTrials.gov record NCT02959060. Inclusion in this directory is not an endorsement.